Sarah Young has been appointed as the executive director of the Prescription Drug Affordability Board and the Drug Price Transparency Program in Oregon. This announcement was made by the Oregon Division of Financial Regulation (DFR). Young’s extensive experience in health policy, particularly in rural healthcare, positions her to address the pressing issues related to drug affordability in the state.
Beginning her role on October 6, 2023, Young previously led the policy and research division at the Federal Office of Rural Health Policy, where she managed a team of 17 and oversaw critical policy analysis and emergency response programs. Her return to Oregon is seen as a significant step forward in tackling the challenges of prescription drug costs and transparency.
Expertise in Health Policy
TK Keen, the DFR administrator and acting insurance commissioner, expressed enthusiasm about Young’s appointment, stating, “We were very fortunate to get someone with Sarah’s expertise and experience who wanted to come back to Oregon.” Keen emphasized that Oregonians can anticipate valuable insights from Young’s federal experience, which will enhance the state’s efforts to improve drug affordability.
Young’s notable contributions include managing the Rural Health Clinic COVID-19 response and enhancing quality of care and operational efficiency within Critical Access Hospitals. Her academic credentials include a master’s degree in public health from Portland State University, further solidifying her readiness for this critical role.
New Perspectives in Drug Pricing
Joining Young in the mission to reform drug pricing is Michele Yoder, a new member of the board who brings extensive experience as the pharmacy director for the Multnomah County Health Department. Yoder has previously served on the Oregon Pain Management Commission and the Oregon Health Resources Commission from 2013 to 2021, providing her with valuable insights into health policy complexities.
The board has also confirmed the reappointments of Dan Hartung, Christopher Laman, and Dan Kennedy, ensuring a blend of continuity and fresh perspectives in their approach. Together, this team aims to develop equitable drug pricing strategies and enhance transparency in the pharmaceutical landscape.
As Oregon continues to grapple with rising prescription drug costs, the appointment of Sarah Young and her team marks a pivotal moment in the state’s efforts to promote affordability and accessibility for its residents. The initiative reflects a broader commitment to improving health outcomes and ensuring that essential medications are within reach for all Oregonians.
